SEL 212

Drug Profile

SEL 212

Alternative Names: Non-immunogenic uricase; Pegadricase-SVP; Pegsiticase-SVP; SEL-037/SEL-110; SEL-212; SVP-Rapamycin/pegsiticase

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selecta Biosciences
  • Class Antigouts; Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout

Most Recent Events

  • 08 Aug 2018 Selecta plans a phase III trial for Gout, in the fourth quarter of 2018
  • 15 Jun 2018 Updated efficacy, immunogenicity and safety data from a phase II trial in Gout presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 10 Apr 2018 Updated efficacy and adverse events data from a phase II trial in Gout released by Selecta Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top